18 April 2007
NNE Pharmaplan has today been officially launched as a joint company
following NNE’s acquisition of the German engineering company Pharmaplan
GmbH which was completed on 31 March 2007.
“We will now start integrating the two companies, while maintaining focus on
the daily business of supplying high-quality engineering and consultancy
services to the pharmaceutical and biotechnological industries”, says Hans Ole
Voigt, President of NNE Pharmaplan.
“I am confident that the integration process will be relatively smooth. The
purpose of the merger is to utilise the business synergies and future growth
potential which will be released by unifying two companies with
complementary market presence and competences.”
Pharmaplan supplements NNE with know-how in delivery of turnkey facilities,
validation and key pharmaceutical processes, whereas NNE supplements
Pharmaplan in areas such as biotechnology, cleanroom and automation.
“NNE Pharmaplan is now a truly global company with a workforce of more than
1500 professionals focused on the pharma and biotech industries. This will
enable us to offer a unique worldwide service to our clients within our field of
expertise and to become a strong candidate for executing large-scale
pharmaceutical projects throughout the world”, says Hans Ole Voigt.
Today, NNE Pharmaplan has five offices in the US market, which is the most
significant market for the life science industry. In the growing markets of India
and China the company has 60 employees in offices in Delhi and Bangalore
and 130 employees in Tianjin, China. Europe and the rest of Asia are covered
by 12 offices, as well as the corporate headquarters in Copenhagen, Denmark,
and a significant Germany hub in Frankfurt.
For further information, please contact:
Hans Ole Voigt, President, NNE Pharmaplan, 0045 30797441
Kasper Riis, Communications Manager, NNE Pharmaplan, 0045 30798316
E-mail: media@nnepharmaplan.com
About NNE Pharmaplan
NNE Pharmaplan is the world's leading engineering and consultancy company that focuses exclusively on the
pharmaceutical and biotechnological industries.